Compound blood pressure lowering pharmaceutical composition and uses thereof

A technology of composition and medicine, applied in the field of compound antihypertensive pharmaceutical composition, to achieve the effect of increasing patient compliance, taking medicine conveniently, and improving the antihypertensive curative effect

Active Publication Date: 2018-10-23
SICHUAN CREDIT PHARMA
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is also no literature report that a certain amount of calcium antagonist is mixed with a certain amount of 5-HT1A receptor agonist to make a compound pharmaceutical preparation for the treatment and control of hypertension

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound blood pressure lowering pharmaceutical composition and uses thereof
  • Compound blood pressure lowering pharmaceutical composition and uses thereof
  • Compound blood pressure lowering pharmaceutical composition and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Preparation of Compound Amlodiplanar Spirone Tablets

[0048]

[0049] Preparation method: mix the raw and auxiliary materials evenly, and directly compress the powder into tablets to make 1,000 tablets to obtain tablets. Each of the prepared compound tablets contains 10 mg of amlodipine besylate and 30 mg of tandospirone citrate.

Embodiment 2

[0051] Preparation of Compound Levoamlodipine Buspirone Besylate Tablets

[0052]

[0053]

[0054] Preparation method: mix levamlodipine besylate, buspirone hydrochloride, hydroxypropyl methylcellulose and starch evenly, sieve, add 75% ethanol solution to granulate, dry at about 50°C, 20 mesh Sieve the granules, add magnesium stearate, mix evenly and press into tablets to make 1000 tablets. Each of the compound tablets made contains 5 mg of levamlodipine besylate and 30 mg of buspirone hydrochloride.

Embodiment 3

[0055] Embodiment 3: Preparation of Compound Nifedipine Lurasidone Tablets

[0056]

[0057] Preparation method: mix the raw and auxiliary materials evenly, and directly compress the powder into tablets to make 1,000 tablets to obtain tablets. Each of the prepared compound tablets contains 30 mg of nifedipine and 60 mg of lurasidone hydrochloride.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides uses of combined application of a calcium antagonist drug and a 5-HT1A receptor agonist drug in preparation of drugs for treatment and prevention of high blood pressure,and a blood pressure lowering pharmaceutical composition, which comprises a therapeutically effective amount of a calcium antagonist and an active metabolite thereof, a therapeutically effective amount of a 5-HT1A receptor agonist and an active metabolite thereof, and a pharmaceutically acceptable carrier. According to the present invention, through the combined application of the calcium antagonist drug and the 5-HT1A receptor agonist drug, the blood pressure lowering effect can be significantly enhanced, and the side effect of the calcium antagonist can be reduced; and particularly comparedto the combined medication, the application of the compound preparation made of the calcium antagonist and the 5-HT1A receptor agonist as the blood pressure lowering drug can achieve the unexpected blood pressure lowering effect and reduce calcium antagonist induced side effects including constipation and tachycardia.

Description

technical field [0001] The invention relates to the field of medicinal chemistry, in particular to the joint administration of antihypertensive drugs and 5-HT1A receptor agonists, a compound antihypertensive drug composition and its application. Background technique [0002] Essential hypertension is one of the most common chronic diseases and is the main cause of serious cardiovascular diseases such as myocardial infarction, stroke, and kidney disease. The prevalence rate of hypertension in my country is 27.2%, and there are more than 130 million patients at present, and the prevalence rate of hypertension is increasing rapidly (compared with the survey in 1991), and the growth rate of the prevalence rate of hypertension among people aged 35 to 44 74% for men and 62% for women (Gu Dongfeng, Jiang He, Wu Xigui, et al. Prevalence, awareness, treatment and control of hypertension in Chinese adults. Chinese Journal of Preventive Medicine, 2003, 37 (2): 84~89). Elevated blood pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/4422A61K31/506A61P9/12
CPCA61K45/06A61K31/4422A61K31/506A61K2300/00
Inventor 陈刚陈功政刘志鸿
Owner SICHUAN CREDIT PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap